Mechanisms of Action and Resistance of HER2 ADCs in Breast Cancer
Introduction Breast cancer is the most common cancer among women worldwide, with approximately 20% of cases being HER2-positive. These patients have a high recurrence rate and poor prognosis. The advent of HER2-targeted monoclonal antibodies such as trastuzumab and pertuzumab has improved the prognosis for patients with HER2-positive advanced breast cancer. In recent years, antibody-drug conjugates … Read more